申请人:The Board of Trustees of the Leland Stanford Junior University
公开号:US10172829B2
公开(公告)日:2019-01-08
Disclosed are methods and compositions for reducing toxicity associated with infection by Clostridium difficile by inhibiting Clostridium difficile toxin B (TcdB) and/or toxin A (TcdA). Such compounds include ebselen compounds, namely ebselen and its salts, ebselen functional analogues and ebselen structural analogues, as well as certain amide derivatives. This includes Formula I, e.g. 1-methyl-3-phenylpropylamine, Formula II, e.g., 2,2′-diselane-1,2-diylbis[N-(2,4-difluorophenyl)benzamide]; and Formula III, e.g. 2-(2-methoxy-5-methylphenyl)-1, 2-benzoselenazol-3-one. The present compositions may be comprised in a colon-retentive formulation that increases residence of and/or release of the compound in the area where the infection is active.
所公开的是通过抑制艰难梭菌毒素B(TcdB)和/或毒素A(TcdA)来降低与艰难梭菌感染相关的毒性的方法和组合物。此类化合物包括依布硒化合物,即依布硒及其盐类、依布硒功能类似物和依布硒结构类似物,以及某些酰胺衍生物。这包括式 I,如 1-甲基-3-苯基丙胺;式 II,如 2,2′-二硒-1,2-二基双[N-(2,4-二氟苯基)苯甲酰胺];以及式 III,如 2-(2-甲氧基-5-甲基苯基)-1,2-苯并硒唑-3-酮。本组合物可包含在一种结肠保留制剂中,以增加化合物在感染活跃区域的停留和/或释放。